Eurofins Scientific has successfully completed the acquisition of Synlab’s clinical diagnostic operations in Spain, an effective move as of March 31, 2025. This purchase strengthens Eurofins’ position, a leading company in bioanalytical testing, in the Spanish market, where Synlab reported revenues exceeding 143 million euros during the year 2024.
Synlab is known for its wide range of diagnostic tests, ranging from genetic services to pathology, and has been operating throughout the national territory. The transaction allows Eurofins, through its Eurofins Megalab network, to further consolidate its leadership in this sector, leveraging the experience and infrastructure that Synlab has developed over the years.
With this acquisition, Eurofins positions itself as the main operator of clinical analysis in Spain, improving its ability to serve both public and private sector clients in various autonomous communities. The company expects to manage more than 10 million patients and process over 100 million tests annually, supported by a highly qualified team of over 2,000 employees.
Eurofins CEO, Dr. Gilles Martin, expressed his excitement for the addition of the Synlab team to their organization, stating: “We are pleased to welcome the Synlab Spain team to Eurofins. With the expansion of our network, we will be able to offer an even wider range of services to our clients, who trust us as a technologically advanced and reference partner.” This strategic move not only reinforces Eurofins’ position in the diagnostic sector in Spain, but also allows for the integration of innovative technology and a high-quality laboratory test portfolio.
Referrer: MiMub in Spanish
